MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]
MSC-Derived Therapeutics and Exosomes as Rising Stars in Advanced Therapeutics
Today, the term MSC describes a class of cells that have historically been known as mesenchymal stem cells, mesenchymal stromal cells, and medicinal signaling cells, among other names. The clinical utility of MSCs is primarily attributed to their key biological properties, which include: [Read more…]
Regenexx – Dr. Chris Centeno on the Orthopedic Applications of MSCs
Regenexx is a U.S. company specializing in orthopedic applications of stem cells that was founded by Dr. Chris Centeno. Dr. Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) in orthopedic applications. His Regenexx clinic in Denver, Colorado, incorporates a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments. [Read more…]
Burgeoning Number of iPSC Therapies To Be Tested in Clinical Trials
Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]
UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study
SHANGHAI, May 23, 2025 — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson’s disease. [Read more…]
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 202
- Next Page »